COVID-19 Monoclonal Antibodies Update

December 27, 2021
All COVID-19 monoclonal antibodies are on national shortage and supply at Novant Health is now extremely low. Effective Monday, Dec. 27, we will begin using sotrovimab for all COVID-19 infusion treatments to align with a North Carolina Department of Health and Human Services directive regarding COVID-19 monoclonal antibodies in the setting of increasing Omicron variant prevalence. Sotrovimab appears to retain activity against Omicron variant. Neither bamlanivimab/etesevimab nor REGEN-COV products are active against Omicron variant. Sotrovimab is not approved for post-exposure prophylaxis. Due to limited sotrovimab supply, we will continue the following conservation strategies:
  • Administration of COVID-19 monoclonal antibodies will be centralized to the infusion centers. No supply is currently available for administration in the emergency departments or for eligible admitted patients.
  • Treatment doses of COVID-19 monoclonal antibodies will be prioritized for unvaccinated, incompletely vaccinated or immunocompromised individuals, and those at high risk for severe disease, hospitalization or death.
  • Patients with symptoms for less than seven days will be prioritized over those with symptoms for eight to 10 days.
    • Patients who qualify for treatment will be contacted by NHRMC to schedule an appointment. If the patient cannot be treated with monoclonal antibodies infusion, the provider will be notified by NHRMC and will contact the patient for other treatment options.
Review the practice alert for more details, and contact pharmacy with questions. Please note this is a fluid situation due to fluctuating supplies and community demand. We will continue to provide updates as changes occur.